tetano
Editor, Senior Moderator
Expert Rev Anti Infect Ther
. 2022 Oct 11.
doi: 10.1080/14787210.2022.2134118. Online ahead of print.
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
Andrew Ustianowski[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: There is a need to protect vulnerable individuals who do not respond to vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), particularly following emergence of new variants. Tixagevimab/cilgavimab, the only monoclonal antibody combination authorized for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19), demonstrated efficacy in unvaccinated individuals in the PROVENT study.
Areas covered: This review focuses predominantly on real-world evidence examining the effectiveness and safety of tixagevimab/cilgavimab in populations who are immunocompromised and otherwise vulnerable. The ability of tixagevimab/cilgavimab to neutralize Omicron subvariants, the appropriate dosage in vulnerable populations, and the impact of prior vaccination on tixagevimab/cilgavimab effectiveness are also discussed.
Expert opinion: The tixagevimab/cilgavimab combination is important in providing protection in people who either cannot have a full vaccination or respond poorly to COVID-19 vaccines. Abundant clinical data have emerged to inform clinical use in adults in need, although some additional data-formal pediatric and adolescent studies, plus information on optimal doses required to protect against emerging variants, and the ideal interval between tixagevimab/cilgavimab dosing and vaccination-would be welcomed. Importantly, despite the current effectiveness of tixagevimab/cilgavimab, we must recognize the possibility that resistant SARS-CoV-2 variants could emerge in the future.
Keywords: COVID-19; Omicron; SARS-CoV-2; cilgavimab; immunocompromised; pre-exposure prophylaxis; tixagevimab; treatment.
. 2022 Oct 11.
doi: 10.1080/14787210.2022.2134118. Online ahead of print.
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
Andrew Ustianowski[SUP] 1 [/SUP]
Affiliations
- PMID: 36217836
- DOI: 10.1080/14787210.2022.2134118
Abstract
Introduction: There is a need to protect vulnerable individuals who do not respond to vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), particularly following emergence of new variants. Tixagevimab/cilgavimab, the only monoclonal antibody combination authorized for pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19), demonstrated efficacy in unvaccinated individuals in the PROVENT study.
Areas covered: This review focuses predominantly on real-world evidence examining the effectiveness and safety of tixagevimab/cilgavimab in populations who are immunocompromised and otherwise vulnerable. The ability of tixagevimab/cilgavimab to neutralize Omicron subvariants, the appropriate dosage in vulnerable populations, and the impact of prior vaccination on tixagevimab/cilgavimab effectiveness are also discussed.
Expert opinion: The tixagevimab/cilgavimab combination is important in providing protection in people who either cannot have a full vaccination or respond poorly to COVID-19 vaccines. Abundant clinical data have emerged to inform clinical use in adults in need, although some additional data-formal pediatric and adolescent studies, plus information on optimal doses required to protect against emerging variants, and the ideal interval between tixagevimab/cilgavimab dosing and vaccination-would be welcomed. Importantly, despite the current effectiveness of tixagevimab/cilgavimab, we must recognize the possibility that resistant SARS-CoV-2 variants could emerge in the future.
Keywords: COVID-19; Omicron; SARS-CoV-2; cilgavimab; immunocompromised; pre-exposure prophylaxis; tixagevimab; treatment.